Abstract
AbstractAimSickle cell disease is a well‐recognized risk factor for the development of osteomyelitis. Its occurrence in the mandible is both complex and challenging. Antibiotics and surgery remain the main treatment modalities, but both have varying success in refractory osteomyelitis. With increasing individual clinical cases highlighting the successful management of both primary and secondary chronic osteomyelitis with bisphosphonate therapy, it was considered a viable last line trial medication prior to aggressive surgery in refractory sickle cell osteomyelitis.Materials and methodsTwo cases are retrospectively reported for the use of oral bisphosphonates.ResultsBoth cases showed positive outcomes both clinically and radiographically in response to oral bisphosphonates with no recurrence of acute episodes even on the background of recurring sickle crises.ConclusionThe current cases are the first in the literature to report successful management of sickle cell osteomyelitis with oral bisphosphonates and explores the literature on previous reports of the condition.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
